Novartis-backed gene therapy player GenSight is looking to bounce back from its failure to list on Nasdaq by pulling off a €40 million IPO in Paris.

He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces…

Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-…

It was a shock result for the U.K. this morning as the public decided by a narrow margin of 52-48 to leave the European Union, in what will have a profound…

On June 17, Neil Woodford upped his stake in Circassia. The next business day, Circassia posted Phase III trial data that caused its stock price to crash.

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-…

The struggling biotech Verastem that has seen its stock nose-dive will look to a future without executive chairman Christoph Westphal and director Henri…

Sorrento Therapeutics has wrapped up a $150 million private placement, giving it money for advance its pipeline and continue its Asian partnership strategy.